SPHK1 and B-cell chronic lymphocytic leukemia: In summary, the reduction in CLL activation exerted by SPHK inhibitors in our system may involve a direct effect on CLL cells and indirect effects on other subpopulations present in PBMC cultures, including CD4+ and CD8+ T cells.